Diagnostic tests are essential to combating antimicrobial resistance (AMR), but developers face myriad challenges getting their tests through FDA, and the ones that do make it to market have to grapple with reimbursement issues, a panel of former FDA officials, academics and industry experts said during a Duke-Margolis webinar last week. The experts, who called for increasing funding for bacterial diagnostics, noted that two bills being considered by Congress -- the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act...